<p>Biotechnology is one of Europe’s most important — and most challenging — innovation sectors. From vaccines and drugs to medical devices and digital medicine, biotech underpins Europe’s health systems,&nbsp;competitiveness&nbsp;and economic sovereignty.&nbsp;</p><p>In this episode of&nbsp;<em>Invested by Europe</em>, Antoine de&nbsp;Lachaux,&nbsp;head of the&nbsp;life&nbsp;science and&nbsp;biotech&nbsp;unit at the European Investment Bank, explains:&nbsp;</p><ul><li>What biotech&nbsp;means&nbsp;— from pharmaceuticals and vaccines to medical devices and digital health&nbsp;</li><li>Why life sciences are strategically important for Europe&nbsp;</li><li>Why biotech innovation takes time, carries&nbsp;high risk&nbsp;and requires patient capital&nbsp;</li><li>How Europe’s fragmented market makes scaling more difficult than in the United States&nbsp;</li><li>What the proposed Biotech Act could change for European companies&nbsp;</li><li>How the EIB supports the sector, including its early investment in BioNTech&nbsp;</li><li>Why artificial intelligence is set to accelerate drug development,&nbsp;diagnostics&nbsp;and regulatory processes&nbsp;</li></ul><p>The conversation also looks at why Europe needs a truly European investment ecosystem to help biotech companies grow to global scale — and why this is a sector Europe cannot afford to outsource.</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>